28th, October 2025
Solupore® Integrated consolidates multiple unit processes into a single core consumable, delivering a closed, automated and sensor‑enabled workflow. This integrated approach reduces facility footprint, streamlines operations and significantly lowers costs while enabling affordable scale‑out and easy adoption through stand-alone consumables.
Current manufacturing workflows rely on up to 8 standalone instruments, leading to fragmented processes and inefficiencies.
Open, manual processes contribute to >10% batch failures, increasing risk and cost.
Manual intervention drives 25–51% of batch costs and limits scalability.
Cleanroom buildouts exceed $1,000 per square foot, creating a major barrier to scale and affordability.
Activation, transduction, expansion, harvest are consolidated into one core consumable.
The smaller, lighter automated units integrate into existing workflows and enable parallel batch processing.
Closed system design, automated sampling and inline pH/DO and CO2 sensors provide full process monitoring and data integrity.
Densification and scale‑out reduce facility footprint and labour, driving significant reductions in cost of goods.
Traditional integrated platforms are designed to process one batch per run. The smaller, lighter Solupore® Integrated allows for parallel processing, increasing the throughput while reducing the space required.
~50 batches per year
Baseline cost
~350 batches per year (600% increase)
75% lower investment
The backbone of our scale‑out architecture: Solupore® Integrated automated manufacturing units are designed for modular, cost‑effective scale out.
High throughput does not need to come at the expense of quality. Solupore® Integrated consistently produces large numbers of potent CAR‑T cells. Sample data shown below for 7-day process.
Total viable cells
(Day 7)
CD19‑CAR+ cells
CD3+ starting cells
CAR expression
Solupore® Integrated yields a product that retains a stem‑like phenotype and shows minimal T‑cell exhaustion. Our 7‑day process delivers potent cells capable of strong cytotoxicity and sustained cytokine release.
Cells maintain a Tscm/Tcm phenotype associated with long‑term persistence.
Low expression of exhaustion markers (PD‑1, LAG‑3, TIGIT) ensures durable function.
Highly cytotoxic at multiple effector‑to‑target ratios with strong cytokine release (IFNγ).
Rapid expansion within 7 days without compromising cell quality.
Solupore® Integrated supports non‑viral editing and expansion within the same closed consumable. Our integrated transfection‑expansion workflow simplifies complex engineering tasks.
High editing efficiency with minimal perturbation
(Day 3)
Large total viable cell output (Day 7)
Editing maintains phenotype and viability
Supports mRNA, CRISPR and HDR workflows
Designed for seamless transition from research use to GMP manufacturing, Solupore® Integrated comes with comprehensive compliance and digitalisation features.
GMP consumable with a Drug Master File (DMF) filed with the FDA.
Automated sampling and in-line pH/DO sensing. Electronic run record with 21 CFR Part II compliance.
US‑established supply chain with qualified suppliers ensures reliability and rapid deployment.
Engineered for smooth scale‑up from research use only (RUO) into full GMP manufacturing.
A core advantage of Solupore® Integrated lies in its ability to reduce the total cost of cell therapy manufacturing. Our consumable‑based approach dramatically reduces facility investment, labour and failure‑related expenses while increasing throughput.
Automation and integration of manufacturing processes greatly reduces labour inputs vs disaggregated processes, reducing COGS by up to 25%.
Densification and parallel processing AMUs decrease cleanroom footprint, reducing facility investment by up to 75% vs other integrated platforms*.
*Based on comparative analysis of equipment costs, labour inputs and facility utilisation versus integrated single‑batch platforms.
Our experienced executive leadership, seasoned board of directors and world‑class scientific advisory board ensure that Solupore® Integrated meets the highest scientific and commercial standards. Learn more about the people behind the platform.
Partner with Avectas to bring scalable, high‑quality therapies to patients worldwide.
